Apellis Pharmaceuticals, Inc. - Common Stock (APLS)
CUSIP: 03753U106
Q2 2025 13F Holders as of 30 Jun 2025
- Type / Class
- Equity / Common Stock
- Shares outstanding
- 130,066,725
- Total 13F shares
- 131,608,288
- Share change
- +4,937,293
- Total reported value
- $2,279,077,423
- Put/Call ratio
- 21%
- Price per share
- $17.31
- Number of holders
- 246
- Value change
- +$66,148,357
- Number of buys
- 147
- Number of sells
- 116
Quarterly Holders Quick Answers
What is CUSIP 03753U106?
CUSIP 03753U106 identifies APLS - Apellis Pharmaceuticals, Inc. - Common Stock in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Related Filing Research
- Latest 13F filings for newly reported positions.
- Latest Schedule 13D/13G reports for ownership changes outside 13F cadence.
- Latest 10-Q/10-K reports for financial context tied to this issuer.
- Recent insider transactions for executive and insider activity.
- SEC investors directory and top value investors for manager drilldown.
- Back to full security ownership history.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 03753U106:
Top shareholders of APLS - Apellis Pharmaceuticals, Inc. - Common Stock (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| Morningside Venture Investments Ltd |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
12,806,342
|
$815,635,922 | — | 18 Nov 2021 | |
| WELLINGTON MANAGEMENT GROUP LLP |
13F
|
Company |
9.5%
|
12,303,252
|
$269,072,121 | — | 31 Mar 2025 | |
| Avoro Capital Advisors LLC |
13F
|
Company |
9.4%
|
12,222,222
|
$267,299,995 | — | 31 Mar 2025 | |
| EcoR1 Capital, LLC |
13F
|
Company |
9.1%
|
11,895,808
|
$260,161,321 | — | 31 Mar 2025 | |
| VANGUARD GROUP INC |
13F
|
Company |
7.8%
|
10,130,356
|
$221,550,886 | — | 31 Mar 2025 | |
| MORGAN STANLEY |
13F
13D/G
|
Company |
7.7%
from 13D/G
|
9,626,123
|
$210,523,336 | — | 31 Mar 2025 | |
| BlackRock, Inc. |
13F
|
Company |
4.9%
|
6,329,598
|
$138,428,308 | — | 31 Mar 2025 | |
| Deep Track Capital, LP |
13D/G
13F
|
Company |
5.6%
|
7,000,000
|
$125,720,000 | $0 | 09 May 2025 | |
| AQR CAPITAL MANAGEMENT LLC |
13F
|
Company |
3.1%
|
4,077,419
|
$89,173,152 | — | 31 Mar 2025 | |
| STATE STREET CORP |
13F
|
Company |
3%
|
3,941,405
|
$86,198,527 | — | 31 Mar 2025 | |
| UBS Group AG |
13F
|
Company |
2.5%
|
3,272,194
|
$71,562,883 | — | 31 Mar 2025 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
2.4%
|
3,131,436
|
$68,484,497 | — | 31 Mar 2025 | |
| Siren, L.L.C. |
13F
|
Individual |
2%
|
2,578,396
|
$56,389,521 | — | 31 Mar 2025 | |
| JENNISON ASSOCIATES LLC |
13F
|
Company |
1.9%
|
2,477,531
|
$54,183,603 | — | 31 Mar 2025 | |
| Octagon Capital Advisors LP |
13F
|
Company |
1.6%
|
2,094,000
|
$45,795,780 | — | 31 Mar 2025 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
1.5%
|
1,950,046
|
$42,661,008 | — | 31 Mar 2025 | |
| DEUTSCHE BANK AG\ |
13F
|
Company |
1.4%
|
1,776,576
|
$38,853,717 | — | 31 Mar 2025 | |
| BRAIDWELL LP |
13F
|
Company |
1.3%
|
1,652,334
|
$36,136,545 | — | 31 Mar 2025 | |
| SUVRETTA CAPITAL MANAGEMENT, LLC |
13F
|
Company |
1.3%
|
1,646,615
|
$36,011,470 | — | 31 Mar 2025 | |
| Polar Capital Holdings Plc |
13F
|
Company |
1.2%
|
1,577,175
|
$34,492,817 | — | 31 Mar 2025 | |
| FMR LLC |
13F
|
Company |
1.2%
|
1,503,209
|
$32,875,187 | — | 31 Mar 2025 | |
| ORBIMED ADVISORS LLC |
13F
|
Company |
1.1%
|
1,432,300
|
$31,324,401 | — | 31 Mar 2025 | |
| BNP PARIBAS FINANCIAL MARKETS |
13F
|
Company |
0.85%
|
1,110,709
|
$24,291,206 | — | 31 Mar 2025 | |
| CANADA PENSION PLAN INVESTMENT BOARD |
13F
|
Company |
0.81%
|
1,048,700
|
$22,935,069 | — | 31 Mar 2025 | |
| Man Group plc |
13F
|
Company |
0.79%
|
1,027,792
|
$22,477,811 | — | 31 Mar 2025 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.74%
|
964,499
|
$21,093,593 | — | 31 Mar 2025 | |
| ROYAL BANK OF CANADA |
13F
|
Company |
0.61%
|
794,935
|
$17,384,000 | — | 31 Mar 2025 | |
| NATIONAL BANK OF CANADA /FI/ |
13F
|
Company |
0.6%
|
782,701
|
$17,117,662 | — | 31 Mar 2025 | |
| Boxer Capital Management, LLC |
13F
|
Company |
0.55%
|
713,000
|
$15,593,310 | — | 31 Mar 2025 | |
| NATIXIS |
13F
|
Company |
0.5%
|
655,027
|
$14,777,409 | — | 31 Mar 2025 | |
| Invesco Ltd. |
13F
|
Company |
0.49%
|
641,397
|
$14,027,353 | — | 31 Mar 2025 | |
| Jefferies Financial Group Inc. |
13F
|
Company |
0.46%
|
599,255
|
$13,105,707 | — | 31 Mar 2025 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.4%
|
518,694
|
$11,343,838 | — | 31 Mar 2025 | |
| Nuveen, LLC |
13F
|
Company |
0.38%
|
492,238
|
$10,765,246 | — | 31 Mar 2025 | |
| AMERIPRISE FINANCIAL INC |
13F
|
Company |
0.36%
|
466,661
|
$10,205,876 | — | 31 Mar 2025 | |
| MILLENNIUM MANAGEMENT LLC |
13F
|
Company |
0.35%
|
451,973
|
$9,884,650 | — | 31 Mar 2025 | |
| Squarepoint Ops LLC |
13F
|
Company |
0.34%
|
442,793
|
$9,683,883 | — | 31 Mar 2025 | |
| JPMORGAN CHASE & CO |
13F
|
Company |
0.33%
|
423,800
|
$9,268,507 | — | 31 Mar 2025 | |
| CITIGROUP INC |
13F
|
Company |
0.32%
|
416,619
|
$9,111,458 | — | 31 Mar 2025 | |
| Trexquant Investment LP |
13F
|
Company |
0.3%
|
384,922
|
$8,418,244 | — | 31 Mar 2025 | |
| SG Americas Securities, LLC |
13F
|
Company |
0.28%
|
366,144
|
$8,008,000 | — | 31 Mar 2025 | |
| Pictet Asset Management Holding SA |
13F
|
Company |
0.24%
|
314,842
|
$7,618,214 | — | 31 Mar 2025 | |
| Amundi |
13F
|
Individual |
0.25%
|
329,582
|
$7,422,187 | — | 31 Mar 2025 | |
| ALGERT GLOBAL LLC |
13F
|
Company |
0.26%
|
338,613
|
$7,405,000 | — | 31 Mar 2025 | |
| 683 Capital Management, LLC |
13F
|
Company |
0.26%
|
333,000
|
$7,282,710 | — | 31 Mar 2025 | |
| Bank of New York Mellon Corp |
13F
|
Company |
0.25%
|
329,173
|
$7,199,013 | — | 31 Mar 2025 | |
| BALYASNY ASSET MANAGEMENT L.P. |
13F
|
Company |
0.25%
|
324,487
|
$7,096,531 | — | 31 Mar 2025 | |
| Lukas Scheibler |
3/4/5
|
Chief Research Officer |
—
mixed-class rows
|
107,690
mixed-class rows
|
$6,961,586 | — | 01 Dec 2023 | |
| Walleye Capital LLC |
13F
|
Company |
0.24%
|
317,442
|
$6,942,457 | — | 31 Mar 2025 | |
| Hudson Bay Capital Management LP |
13F
|
Company |
0.24%
|
310,700
|
$6,795,009 | — | 31 Mar 2025 |
Institutional Holders of Apellis Pharmaceuticals, Inc. - Common Stock (APLS) as of Q2 2025
As of 30 Jun 2025,
Apellis Pharmaceuticals, Inc. - Common Stock (APLS) was held by
246 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
131,608,288 shares.
The largest 10 holders included
Avoro Capital Advisors LLC, EcoR1 Capital, LLC, VANGUARD GROUP INC, MORGAN STANLEY, WELLINGTON MANAGEMENT GROUP LLP, Deep Track Capital, LP, BlackRock, Inc., AQR CAPITAL MANAGEMENT LLC, UBS Group AG, and STATE STREET CORP.
This page lists
246
institutional shareholders reporting positions in this security
for the Q2 2025 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q2 2025 vs Q1 2025 Across Filers
Q1 2025 holders
252
Q2 2025 holders
246
Holder diff
-6
| Investor | Q1 2025 Shares | Q2 2025 Shares | Share Diff | Share Chg % | Q1 2025 Value $ | Q2 2025 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.